Before revision:  Anti-amyloid beta (ABeta) antibodies are the leading drug candidates to treat AD, but the results of clinical trials over the past two decades have been mostly disappointing. This was due to either low effectiveness or serious side effects that emerged during clinical trials.
After revision:  Anti-amyloid beta (ABeta) antibodies are the leading drug candidates to treat AD, but the results of clinical trials have been disappointing.